Drugmaker with rare disease work · based in Gaithersburg, United States · founded 1997 · ticker ALT · altimmune.com
Altimmune is a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for serious liver, metabolic, and cardiometabolic diseases. The company's lead investigational medicine pemvidutide is a balanced glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis and other metabolic disorders.
Altimmune Inc clinical trials
We did not find active Altimmune Inc trials for the rare diseases we track on ClinicalTrials.gov right now.
More about Altimmune Inc
The clinical trials section below shows active and recruiting rare disease studies sponsored by Altimmune Inc, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites.
The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Altimmune Inc is headquartered in Gaithersburg, United States, founded in 1997, publicly traded under the ticker symbol ALT. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. Altimmune Inc's own site is altimmune.com, and our help paying for treatment page lists drugmaker programs and charity funds.
Questions about Altimmune Inc
Altimmune is a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for serious liver, metabolic, and cardiometabolic diseases. The company's lead investigational medicine pemvidutide is a balanced glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis and other metabolic disorders.
Altimmune Inc is a diversified pharmaceutical company headquartered in Gaithersburg, United States, founded in 1997. While it operates across multiple therapeutic areas, it maintains a significant rare disease portfolio with 0 active rare disease programs. Many of its rare disease treatments hold orphan drug designations from the FDA.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by Altimmune Inc, pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
None that we track as of November 2026. No Altimmune Inc label in the FDA's openFDA database matches a rare disease on Trial Friend, which usually means the company has no approved product yet or its approved drugs are for common conditions.
In development: the trials list on this page shows what Altimmune Inc is recruiting for now, and the FDA calendar lists any application once a decision date is public.
Altimmune Inc was founded in 1997 and is headquartered in Gaithersburg, United States. The company has been active for 29 years. It trades publicly under the ticker symbol ALT.